Radzikowska Joanna, Krzeski Antoni, Czarnecka Anna M, Klepacka Teresa, Rychlowska-Pruszynska Magdalena, Raciborska Anna, Dembowska-Baginska Bozenna, Pronicki Maciej, Kukwa Andrzej, Sierdzinski Janusz, Kukwa Wojciech
Department of Otorhinolaryngology, Faculty of Dental Medicine, Medical University of Warsaw, 19/25 Stepinska St., 00-739 Warsaw, Poland.
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, 5 Roentgena St., 02-781 Warsaw, Poland.
J Clin Med. 2021 Feb 1;10(3):512. doi: 10.3390/jcm10030512.
(1) Background: The study proposed to analyze microvessel density (MVD) in rhabdomyosarcoma (RMS) based on the expression of angiogenesis markers and define its prognostic role in this group of patients. (2) Methods: The study included forty-nine pediatric patients diagnosed with RMS. Tumor tissue expression of CD31, CD34, and CD105 was analyzed. MVD was calculated and correlated with clinical RMS prognostic parameters. (3) Results: CD31, CD34, and CD105 are expressed in all RMS cases. MVD/CD105 was significantly higher in the RMS group than in the control group. The mean and median values of MVD/CD105 in RMS were lower than MVD/CD31 and MVD/CD34. MVD/CD105 was significantly higher in patients with alveolar RMS and those with metastatic disease. Patients with higher levels of MVD/CD105 had a higher risk of death (HR = 1.009). (4) Conclusion: CD105 is a relevant angiogenesis marker in pediatric RMS, and MVD/CD105 is an independent risk factor of short overall survival in children with RMS.
(1) 背景：本研究旨在基于血管生成标志物的表达分析横纹肌肉瘤（RMS）中的微血管密度（MVD），并确定其在该组患者中的预后作用。(2) 方法：该研究纳入了49例诊断为RMS的儿科患者。分析肿瘤组织中CD31、CD34和CD105的表达。计算MVD并将其与临床RMS预后参数相关联。(3) 结果：所有RMS病例中均表达CD31、CD34和CD105。RMS组中MVD/CD105显著高于对照组。RMS中MVD/CD105的均值和中位数低于MVD/CD31和MVD/CD34。在腺泡状RMS患者和有转移疾病的患者中，MVD/CD105显著更高。MVD/CD105水平较高的患者死亡风险更高（HR = 1.009）。(4) 结论：CD105是儿科RMS中一种相关的血管生成标志物，且MVD/CD105是RMS患儿总生存期短的独立危险因素。
